The company will deliver its Covid-19 tests, as well as associated consumables, to help respond to a rapid surge of Flu A and Covid-19 infections in Brazil.
According to Seegene, more than 280,000 cases of Covid-19 a day were recently reported in the country.
The firm will deliver its Allplex SARS-CoV-2/FluA/FluB/RSV PCR assay, which has the capability to detect influenza A and B, Covid-19, and respiratory syncytial virus (RSV) in a single test.
Allplex is expected to be the optimised test for the ‘twindemic’ in Brazil, as it can distinguish between Flu A and Covid-19 cases.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The multiplex real-time PCR assay received approval from Health Canada under its Interim Order last month. It enables the simultaneous amplification and differentiation of respiratory symptoms.
Seegene chief sales and marketing officer Ho Yi said: “Seegene is uniquely positioned to respond to the growing global need for Covid-19 and flu testing and we are fully prepared to supply global inventory to help countries around the world as they fight for everyday life to return.”
Last month, the company launched the Allplex SARS-CoV-2 Fast PCR Assay, which is designed to target the E, RdRP and N Covid-19 genes in order to detect the disease regardless of the variant.
Optimised for mass testing, the test provides PCR results in 60 minutes and helps laboratories scale up testing volume without additional instruments.
The launch comes in response to the rapid spread of the Omicron variant across the globe.